Navigation Links
Celleration, Inc. Announces First Patient Enrollment in In-Balance VLU Randomized Control Trial
Date:5/14/2012

EDEN PRAIRIE, Minn., May 14, 2012 /PRNewswire/ -- Celleration, Inc., a privately-held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announced the first patient enrollment in IN-BALANCE VLU (Inflammation, Bacteria, & Angiogenesis effects in Launching Venous Leg Ulcer healing: A Clinical Evaluation).  IN-BALANCE VLU is designed to expand on the vast body of evidence on MIST Therapy® that currently includes 12 peer-reviewed studies and a 444 patient meta-analysis supporting the clinical and economic benefits of the FDA cleared wound healing therapy.

IN-BALANCE VLU is a prospective, randomized, controlled, multi-center study of MIST Therapy in chronic lower extremity venous ulcers ("VLU").  The study will compare the effect of MIST Therapy on wound healing rates to traditional standard of care. The study will be performed at up to 20 study centers with an estimated 124 subjects enrolled in the study overall.  This study also includes sub-analyses of fluid and tissue samples to characterize cellular and molecular changes surrounding inflammation, angiogenesis and bio-burden impact of the treatments.

Venous leg ulcers are estimated to cost the U.S. healthcare system approximately $2-$3 billion annually and cause the loss of approximately two million working days per year. "With the significant economic and social cost of wound care rapidly rising, we must focus on conducting rigorous studies to fully understand both the biological mechanisms and healing outcomes of the many wound care treatment options to ensure we are selecting the most clinically efficacious and cost-effective treatment for each unique patient and wound," commented Gary Gibbons, MD, South Shore Hospital Center for Wound Care and Hyperbaric Medicine, Weymouth, MA.  "Celleration's IN-BALANCE VLU is a very well-designed study that will significantly add to the body of evidence surrounding venous leg ulcer prevention, education and management and in particular the role of advanced therapies like MIST."

"The design of IN-BALANCE VLU was based on input from the world's leading wound care clinicians and researchers," commented Mark Wagner, Celleration's president and CEO. "We believe the results from IN-BALANCE VLU will clearly differentiate MIST Therapy from the vast array of wound care options by providing compelling evidence of superior healing rates and a thorough understanding of the mechanism of actions of MIST Therapy."

About Celleration, Inc.:

Celleration, Inc. is a privately-held medical device company. Celleration develops and markets a proprietary technology that has been proven to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface.  Celleration's core product, the MIST Therapy System, has been clinically shown to positively impact all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating non-healing wounds.   MIST Therapy has been performed more than 900,000 times on over 60,000 patients.

 

 

 


'/>"/>
SOURCE Celleration, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Celleration, Inc. Announces Close of $8 Million Series E Financing
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... 27 Avril 2016   ... de +5% sur le trimestre, soutenu par une ... Croissance de +16% des ventes aux ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), ... annonce aujourd,hui son chiffre d,affaires pour le premier ...
Breaking Medicine Technology:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of a growth round of funding led by Eastside Partners, with participation from ... company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
(Date:4/29/2016)... ... 29, 2016 , ... Intellitec Solutions is pleased to announce ... GP for one their long-term care clients. Working together with the clients staff, ... clinical management systems, and delivered a fully integrated accounting and business-management solution that ...
(Date:4/29/2016)... ... 2016 , ... The number of chronically and seriously ill individuals is growing. ... an urgent need for highly skilled care managers and care coordinators. Care ... train and retain care managers, and enhance their skills. , Care Excellence ...
(Date:4/28/2016)... ... 2016 , ... The Dentists Insurance Company (TDIC), ... letter of intent with Moda to acquire Dentists Benefits Insurance Company ... by dentists 36 years ago, TDIC focuses exclusively on supporting the dental profession ...
Breaking Medicine News(10 mins):